CYTOSORBENTS CORPORATION: accumulated other comprehensive income or loss

What this measure means

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

Exact concept: us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax. Each value is a balance at the reporting date, not a flow earned over a year. Different units remain separate; no currency conversion or interpolation is applied.

Coverage of this history

Selected reporting periods run from 2012-12-31 to 2025-12-31. The SEC response was captured on 2026-09-20.

Selected filing history

Related financial histories

• CYTOSORBENTS CORPORATION: total assets
• CYTOSORBENTS CORPORATION: total liabilities
• CYTOSORBENTS CORPORATION: stockholders equity
• CYTOSORBENTS CORPORATION: cash and cash equivalents
• CYTOSORBENTS CORPORATION: net income or loss
• CYTOSORBENTS CORPORATION: operating cash flow
• CYTOSORBENTS CORPORATION: capital expenditure payments
• CYTOSORBENTS CORPORATION: revenue
• CYTOSORBENTS CORPORATION: financing cash flow
• CYTOSORBENTS CORPORATION: investing cash flow
• CYTOSORBENTS CORPORATION: retained earnings or deficit
• CYTOSORBENTS CORPORATION: basic weighted-average shares
• CYTOSORBENTS CORPORATION: diluted weighted-average shares
• CYTOSORBENTS CORPORATION: basic earnings per share
• CYTOSORBENTS CORPORATION: diluted earnings per share
• CYTOSORBENTS CORPORATION: income tax expense or benefit
• CYTOSORBENTS CORPORATION: net property, plant and equipment
• CYTOSORBENTS CORPORATION: share-based compensation expense
• CYTOSORBENTS CORPORATION: operating income or loss
• CYTOSORBENTS CORPORATION: current assets
• CYTOSORBENTS CORPORATION: current liabilities
• CYTOSORBENTS CORPORATION: current accounts payable
• CYTOSORBENTS CORPORATION: net finite-lived intangible assets
• CYTOSORBENTS CORPORATION: net current accounts receivable
• CYTOSORBENTS CORPORATION: operating expenses
• CYTOSORBENTS CORPORATION: net inventory
• CYTOSORBENTS CORPORATION: gross profit
• CYTOSORBENTS CORPORATION: selling, general and administrative expense
• CYTOSORBENTS CORPORATION: research and development expense
• CYTOSORBENTS CORPORATION: common shares outstanding
• CYTOSORBENTS CORPORATION: cash including restricted cash
• CYTOSORBENTS CORPORATION: additional paid-in capital
• CYTOSORBENTS CORPORATION: operating lease right-of-use asset
• CYTOSORBENTS CORPORATION: operating lease liability
• CYTOSORBENTS CORPORATION: long-term debt
• CYTOSORBENTS CORPORATION: gross property, plant and equipment
• CYTOSORBENTS CORPORATION: accumulated depreciation on property, plant and equipment
• CYTOSORBENTS CORPORATION: other noncurrent assets
• CYTOSORBENTS CORPORATION: accrued current liabilities
• CYTOSORBENTS CORPORATION: prepaid expenses and other current assets
• CYTOSORBENTS CORPORATION: current contract liabilities
• CYTOSORBENTS CORPORATION: net deferred tax assets
• CYTOSORBENTS CORPORATION: pre-tax income or loss from continuing operations
• CYTOSORBENTS CORPORATION: comprehensive income or loss
• CYTOSORBENTS CORPORATION: net income available to common stockholders
• CYTOSORBENTS CORPORATION: depreciation expense
• CYTOSORBENTS CORPORATION: nonoperating income or expense
• CYTOSORBENTS CORPORATION: interest paid, net
• CYTOSORBENTS CORPORATION: proceeds from issuing common stock
• CYTOSORBENTS CORPORATION: operating lease payments
• CYTOSORBENTS CORPORATION: change in accounts receivable
• CYTOSORBENTS CORPORATION: change in inventories

Inspect the source

Entity

CYTOSORBENTS CORPORATION / CIK 0001175151

Captured

2026-09-20T07:44:44.168Z

SEC response SHA-256

8bb195ec858f16302b2a8454a5ffe3eff6c1e6cd0312136a64a7a2f621b86836

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

• Get an API key and run your first validation
• Connect the MCP server to your coding assistant
• Inspect the ALPHAC engine on GitHub
• Read the MCP server source and integration examples

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001175151.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))